Briviact Use In Pregnancy & Lactation

Women of childbearing potential: Physicians should discuss family planning and contraception with women of childbearing potential taking brivaracetam (see Pregnancy as follows).
If a woman decides to become pregnant, the use of brivaracetam should be carefully re-evaluated.
Pregnancy: Risk related to epilepsy and antiepileptic medicinal products in general: For all anti-epileptic drugs, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3% in the general population. In the treated population, an increase in malformations has been noted with polytherapy; however, the extent to which the treatment and/or the underlying condition is responsible has not been elucidated. Discontinuation of anti-epileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.
Risk related to brivaracetam: There is a limited amount of data from the use of brivaracetam in pregnant women. There is no data on placental transfer in humans, but brivaracetam was shown to readily cross the placenta in rats (see Pharmacology: Toxicology: Preclinical safety data under Actions). The potential risk for humans is unknown. Animal studies did not detect any teratogenic potential of brivaracetam (see Pharmacology: Toxicology: Preclinical safety data under Actions).
In clinical studies, brivaracetam was used as adjunctive therapy and when it was used with carbamazepine, it induced a dose-related increase in the concentration of the active metabolite, carbamazepine-epoxide (see Interactions). There is insufficient data to determine the clinical significance of this effect in pregnancy.
As a precautionary measure, brivaracetam should not be used during pregnancy unless clinically necessary (i.e. if the benefit to the mother clearly outweighs the potential risk to the foetus).
Breast-feeding: It is unknown whether brivaracetam is excreted in human breast milk. Studies in rats have shown excretion of brivaracetam in breast milk (see Pharmacology: Toxicology: Preclinical safety data under Actions). A decision should be made whether to discontinue breastfeeding or to discontinue brivaracetam, taking into account the benefit of the medicinal product to the mother. In case of co-administration of brivaracetam and carbamazepine, the amount of carbamazepine-epoxide excreted in breast milk could increase. There is insufficient data to determine the clinical significance.
Fertility: No human data on the effect of brivaracetam on fertility are available. In rats, there was no effect on fertility with brivaracetam (see Pharmacology: Toxicology: Preclinical safety data under Actions).